Literature DB >> 16382212

Plasma concentrations of adhesion molecules and chemokines in patients with essential hypertension.

Andrzej Madej1, Bogusław Okopień, Jan Kowalski, Maciej Haberka, Zbigniew S Herman.   

Abstract

Arterial hypertension vascular injury results in serious complications, such as left-ventricular hypertrophy and myocardial failure, ischemic heart disease and cerebral stroke. Currently, it is well known that inflammatory factors play a significant role in the mechanisms that trigger and enhance the remodeling of the vascular wall. A number of data suggest an important role of adhesion molecules and chemokines in this processes. The aim of this study was measuring the plasma levels of soluble Intercellular Adhesion Molecule 1 (sICAM-1) and Monocyte Chemoattractant Peptide1 (MCP-1) in patients with essential hypertension vs. healthy volunteers by ELISA method (R&D kits). sICAM-1 and MCP-1 levels were significantly higher in hypertensive patients compared to controls (sICAM-1: 279.2 +/- 8.8 ng/ml vs. 224.4 +/- 1.8 ng/ml; p < 0.001; MCP-1: 142.2 +/- 7 pg/ml vs. 95.4 +/- 36 pg/ml; p < 0.0001. Our results indicate that arterial hypertension alone (without inflammation, lipid and carbohydrate disorders) may increase the expression of these cytokines and contribute to the progression of endothelial injury.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16382212

Source DB:  PubMed          Journal:  Pharmacol Rep        ISSN: 1734-1140            Impact factor:   3.024


  11 in total

Review 1.  Interactions Between the Immune and the Renin-Angiotensin Systems in Hypertension.

Authors:  Nathan P Rudemiller; Steven D Crowley
Journal:  Hypertension       Date:  2016-06-27       Impact factor: 10.190

Review 2.  Salt, Hypertension, and Immunity.

Authors:  A Justin Rucker; Nathan P Rudemiller; Steven D Crowley
Journal:  Annu Rev Physiol       Date:  2017-11-16       Impact factor: 19.318

3.  sICAM-1 measurements are independent of processing method and sampling site in patients with coronary artery disease.

Authors:  V L Benson; A C McMahon; H C Lowe
Journal:  J Thromb Thrombolysis       Date:  2007-03-31       Impact factor: 2.300

Review 4.  The role of macrophages in hypertension and its complications.

Authors:  A Justin Rucker; Steven D Crowley
Journal:  Pflugers Arch       Date:  2017-03-01       Impact factor: 3.657

5.  Serum level of soluble intercellular adhesion molecule-1 correlates with pulmonary arterial pressure in children with congenital heart disease.

Authors:  Kanrawee Sungprem; Apichai Khongphatthanayothin; Patchara Kiettisanpipop; Pairoj Chotivitayatarakorn; Yong Poovorawan; Pornthep Lertsapcharoen
Journal:  Pediatr Cardiol       Date:  2009-01-30       Impact factor: 1.655

6.  Improvement in middle cerebral artery structure and endothelial function in stroke-prone spontaneously hypertensive rats after macrophage depletion.

Authors:  Paulo W Pires; Saavia S Girgla; Jonathon L McClain; Norbert E Kaminski; Nico van Rooijen; Anne M Dorrance
Journal:  Microcirculation       Date:  2013-10       Impact factor: 2.628

Review 7.  Pivotal roles of monocytes/macrophages in stroke.

Authors:  Tsuyoshi Chiba; Keizo Umegaki
Journal:  Mediators Inflamm       Date:  2013-01-27       Impact factor: 4.711

8.  Interleukin-1β accelerates the onset of stroke in stroke-prone spontaneously hypertensive rats.

Authors:  Tsuyoshi Chiba; Tatsuki Itoh; Masaki Tabuchi; Toru Nakazawa; Takao Satou
Journal:  Mediators Inflamm       Date:  2012-12-27       Impact factor: 4.711

Review 9.  The varying roles of macrophages in kidney injury and repair.

Authors:  Yi Wen; Steven D Crowley
Journal:  Curr Opin Nephrol Hypertens       Date:  2020-05       Impact factor: 3.416

10.  Effects of nebivolol on endothelial gene expression during oxidative stress in human umbilical vein endothelial cells.

Authors:  Ulisse Garbin; Anna Fratta Pasini; Chiara Stranieri; Stefania Manfro; Chiara Mozzini; Veronica Boccioletti; Andrea Pasini; Mattia Cominacini; Stefano Evangelista; Luciano Cominacini
Journal:  Mediators Inflamm       Date:  2008       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.